IPOX® CEO Josef Schuster featured on the First Trust ROI Podcast to discuss post-IPO performance trends, renewed activity in the IPO market, and key dynamics shaping new listings. Schuster highlighted IPOX® research on the long-term divergence between IPO winners and underperformers, the role of diversification in post-IPO investing, and opportunities across IPOs, spin-offs, SPACs, and international markets as investor interest in newly public companies continues to strengthen.

IPOX® Associate Muehlbauer commented on Lime’s planned U.S. IPO in Reuters, highlighting the Uber-backed electric bike and scooter operator’s global scale, cash generation, and strong revenue growth as supportive factors for its proposed valuation of up to $1.66 billion. His analysis also noted key market considerations, including seasonality, regulation, asset intensity, and city-level permit exposure, as Lime prepares to list on Nasdaq under the ticker LIME.

IPOX® Associate Muehlbauer was quoted by Reuters on Kardigan’s Nasdaq debut, after the heart drug developer raised $400 million in an upsized IPO. He noted that biotech IPO activity has improved but remains selective, favoring companies with late-stage assets, clear commercialization paths, visible catalysts, or strong backers. In broader commentary shared with Reuters, Muehlbauer said Kardigan’s going-concern warning was not a deal breaker and reflected why the company raised capital, while follow-on offerings remain a possible overhang for investors.

U.S. IPO news included SpaceX’s post-debut pullback, Doncasters’ planned listing at up to a $4.43 billion valuation, Brookfield-backed Csquare’s NYSE filing amid AI infrastructure demand, and renewed SPAC interest. Asia-Pacific activity featured Mynt’s Philippine IPO targeting $1 billion and an $8 billion valuation, MetaX’s planned Hong Kong listing of at least $1 billion, Xiaohongshu’s Hong Kong IPO ambitions, Alebund’s $200 million–$300 million Hong Kong IPO, and Qiandaohu’s $150 million–$200 million caviar IPO pipeline across U.S. and Asia-Pacific markets this week.

IPOX® VP Kat Liu was quoted by Reuters on SpaceX’s post-IPO share decline, as the stock fell more than 6% after a sharp debut rally. Reuters reported that shares remained over 30% above the $135 offering price, while investors weighed valuation, limited float, retail activity and AI expansion plans. Liu noted that profit-taking was not surprising given the IPO’s scale and strong initial performance, calling it an eventful, shortened trading week for the largest IPO in history.

IPOX® Associate Muehlbauer noted in Reuters coverage that some companies previously considering a traditional IPO may now look to SPAC mergers as mega-IPOs compete for investor attention. He said existing SPAC vehicles still need to complete transactions before liquidation, leaving capital actively seeking deals. Reuters highlighted renewed SPAC activity and rising issuance, while IPOX® data show the IPOX® SPAC Index outperforming the S&P 500 year to date, up 16.43% versus 9.73% amid a more favorable public-market backdrop for new listings.

In a First Trust webinar, IPOX® CEO Dr. Josef Schuster discussed the SpaceX IPO, strong new-listings activity, and IPOX®’s data-driven approach to tracking IPOs, spin-offs, de-SPACs, REITs, and select IPO M&A. Schuster addressed SpaceX’s expected low float, aftermarket risks, and broader opportunities across the IPO market. The webinar also highlighted the IPOX® 100 U.S. Index, its 20-year live track record, and its role as the underlying index for the First Trust US Equity Opportunity Index (Ticker FPX) today.

IPOX® Associate Muehlbauer commented in Reuters on Doncasters’ planned U.S. IPO, as the aerospace parts maker targets a valuation of up to $4.43 billion and seeks to raise as much as $746.7 million. Muehlbauer noted that aerospace and defense sector momentum could support strong pricing, especially for companies showing demand through government contracts, long-term agreements and backlogs. He also cautioned that investors will focus on whether Doncasters’ capacity investments can translate into profits as it remains loss-making during expansion.

IPO activity remains concentrated in the U.S., led by SpaceX, OpenAI, SK Hynix, Bending Spoons, and Kakao Mobility, while biotech names Parabilis and Kardigan show renewed sector momentum. Asia-Pacific listings focus on Hong Kong robotics, AI, parking technology, and an ASX gold spin-off. In MENA, Saudi offerings face weaker sentiment, with Arabian Dyar shelving plans and Mutlaq Al-Ghowairi withdrawing its $800 million IPO, despite Ninja testing appetite for a possible $1 billion deal. Overall, mega deals dominate investor attention globally now.

IPOX® CEO Josef Schuster was featured in Nikkei, commenting on SpaceX’s Nasdaq debut and its implications for future large IPOs. Schuster said the strong post-listing performance reflected robust demand and highlighted the depth of U.S. capital markets. The article also cited Jay Ritter, who cautioned that SpaceX’s high price-to-sales ratio and speculative growth areas could create downside risk. Schuster noted that news may drive shares short term, while fundamentals will become more important after earnings reports for investors and markets.

IPOX® Associate Lukas Muehlbauer was cited by Reuters on Kardigan’s planned U.S. IPO, which targets a valuation of up to $1.4 billion and aims to raise as much as $373.3 million. Muehlbauer noted a “clear uptick in biotech IPOs” and said healthcare IPO activity has already surpassed last year’s deal flow, signaling an open window for the sector. He also cautioned that investors remain selective, favoring companies with clinical progress and clearer paths to FDA approval.

IPOX® Associate Muehlbauer was interviewed for ZEIT ONLINE, the digital news platform of the German weekly newspaper DIE ZEIT, on the market impact of major planned IPOs and new share offerings. He discussed SpaceX’s expected $75 billion raise, possible listings from leading AI companies, and the challenge of absorbing significant new equity supply. He also noted that later insider sales may be the more important liquidity test for investors after the initial IPO.

IPOX® Associate Dr. Lukas Muehlbauer was quoted by Reuters on ERock’s NYSE debut after the gas generator maker’s shares opened below their IPO price, valuing the company at $5.49 billion. Muehlbauer said investors were pushing back on valuation amid execution risk, noting that ERock’s growth angle is tied to a substantial backlog from data center power demand, but the market wants proof that backlog can convert into revenue before assigning the company a more premium public-market valuation after its listing.

Bloomberg featured IPOX® Founder and CEO Josef Schuster in an interview with Matt Miller on “Bloomberg Deals,” titled “The Golden Age of IPOs is Here: IPOX’s Schuster.” The segment discussed SpaceX’s planned IPO, expected to raise about $75 billion and rank as the largest IPO ever. Schuster joined the program to provide IPOX®’s perspective on the broader IPO market and the current wave of major listings.

IPOX® Associate Lukas Muehlbauer was quoted by Reuters on Parabilis Medicines’ upsized U.S. IPO, which targets a valuation of nearly $2.3 billion as biotech listings regain momentum. Muehlbauer said the larger offering signals a healthier biotech IPO pipeline, while noting investors remain selective and favor larger, better-backed deals. He also highlighted Parabilis’ Regeneron partnership as an external validation of the company’s technology and a source of added credibility ahead of its expected Nasdaq debut under ticker PBLS.

IPOX® CEO Josef Schuster was featured in Reuters’ View article on OpenAI’s confidential U.S. IPO filing, which examined how major AI companies are moving toward public markets. Schuster commented that SpaceX, OpenAI, and Anthropic are seeking public-market capital to finance significant growth, while noting that investors may both reward and punish these companies as their fundamentals develop. He also highlighted that their offering size and initial float could make post-listing trading highly dynamic over time for investors and markets alike.

Global IPO activity is accelerating, led by SpaceX’s planned $75 billion Nasdaq debut and strong demand from Japanese retail investors. AI remains the dominant theme, with Anthropic confidentially filing, OpenAI advancing bank discussions, and ERock, INNIO and Quantinuum drawing investor attention across data-center power and frontier technology. Outside the U.S., Apotex may revive Toronto issuance, Bohus and Magnora expand Oslo listings, Go advances in Tokyo, Anker targets Hong Kong and CANAL+ strengthens its African market presence in Johannesburg this cycle.